September 26, 2011
NIH Director’s Awards go to three JHU scientists for work that challenges status quo, speeds translation of research
A pioneer in the field of epigenetics who has been spearheading the use of genomewide technology for epigenetics research, a researcher who has revealed a weakness in the tuberculosis bacterium that makes it more susceptible to antibiotics and a scientist who seeks to revolutionize new methods for toxicological testing to improve human health and reduce animal testing have received Director’s Awards from the National Institutes of Health.
Andrew P. Feinberg, the King Fahd Professor of Molecular Medicine; a professor in the departments of Molecular Biology and Genetics and of Oncology; and director of the Center for Epigenetics in the Institute for Basic Biomedical Sciences, all at the Johns Hopkins University School of Medicine, is one of 13 winners this year of the Director’s Pioneer Award, which confers $2.5 million in direct funding over five years.
Microbial geneticist Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in research funding over five years.
Thomas Hartung, director of the Center for Alternatives to Animal Testing at the Johns Hopkins Bloomberg School of Public Health, where he is the inaugural holder of the Doerenkamp-Zbinden Endowed Chair in Evidence-based Toxicology in the Department of Environmental Health Sciences, is one of 17 recipients of a $5 million Transformative Research Projects Award.
“The NIH Director’s Award programs reinvigorate the biomedical workforce by providing unique opportunities to conduct research that is neither incremental nor conventional,” said James M. Anderson, director of the NIH’s Division of Program Coordination, Planning and Strategic Initiatives, who guides the NIH Common Fund’s High-Risk Research program. “The awards, this year totaling $143.8 million, are intended to catalyze giant leaps forward for any area of biomedical research, allowing investigators to go in entirely new directions.”
Andrew Feinberg’s groundbreaking research involving non-DNA sequence-related heredity spans three decades; his early studies of epigenetic alterations of genes in human cancer were controversial. Because epigenetics involves the relationship between an individual’s genetic background, the environment, aging and diseases such as cancer, it is today at the epicenter of modern medicine.
“I feel incredibly lucky to receive this award,” Feinberg said. “It gives me the chance to test a unified theory I’ve been developing for understanding the relationship between normal development, epigenetics and evolutionary selection in a changing environment. I plan to test the model in ways I never could with regular grant funding; for example, by genetic and epigenetic analysis of honeybees, which show remarkable epigenetic plasticity that is environmentally sensitive, and a relatively small genome compared to other model organisms.”
Based on the results of recently published research using the latest gene-sequencing tools to examine epigenetic influences on the DNA makeup of colon cancer, Feinberg suggests that cancer treatment might eventually be more tolerable and successful if therapies could focus on helping cancer cells get back to normal, in addition to strategies for killing them. His team focused on a particular epigenetic biochemical signature known as methylation, which silences genes. Although not part of a gene’s central DNA sequence, it is copied when a cell divides, perpetuating its activity.
“The most exciting medical idea in epigenetics is that it might be possible to intervene at the junction between the genome and the environment to modify the effects of deleterious genes, and to influence the effects of the environment on us, perhaps influencing aging or mastering tissue reprogramming in regenerative medicine,” Feinberg said. “We’re only just now really seeing how large its impact might be, and so it’s surprising to be recognized for the work done in my laboratory.”
Gyanu Lamichhane has discovered the key role of enzyme L,D-transpeptidase in forming chemical linkages inside the protective cell wall in Mycobacterium tuberculosis, the bacterium responsible for TB diseases. The same enzyme and chemical linkages help hold together the cell walls of other disease-causing bacteria, including salmonella, Enterococcus and Escherichia coli.
Lamichhane’s recent research shows that when L,D-transpeptidase is unable to function, especially in chronic infections when the enzyme is more active, the TB bacterium loses its virulence, as chemical linkage formation stalls and the bacterial cell wall weakens. This, in turn, exposes other chemical linkages holding the cell wall together, linkages that are known targets of widely prescribed beta-lactam drugs, such as amoxicillin.
As part of the new project, Lamichhane plans to investigate chemicals that interfere with L,D-transpeptidase activity and whether these compounds, when used in combination with antibiotics, hasten treatment of chronic TB or other kinds of bacterial infection. He will also study the enzyme’s fundamental role in the physiology of the bacterial cell wall.
“Our research shows the potential for relatively simple genetic observations about bacterial enzymes to have a broad and powerful impact on possible treatments for a host of infectious diseases,” said Lamichhane, an assistant professor in the Johns Hopkins School of Medicine.
“As a whole new class of drugs, L,D-transpeptidase inhibitors, plus antibiotics, could potentially shorten TB treatment, which now takes a minimum of six months, and it could offer new treatment options to people who have developed drug resistance,” he said.
Experts estimate that 2 billion people worldwide are infected with tuberculosis, 10 million of whom fall ill each year. Tuberculosis is the leading cause of death among people co-infected with HIV, the virus that causes AIDS, leading to some half-million deaths annually among those co-infected.
As the director of CAAT, Transformative Research Projects Award recipient Thomas Hartung received the funding for a consortium to develop a new technological methodology for mapping the molecular pathways of toxicity within cells. CAAT’s ambitious goal is a comprehensive understanding of molecular “pathways of toxicity” that lead to adverse health effects when perturbed. “Mapping the entirety of these pathways—which I’ve termed the ‘Human Toxome’—will be a large-scale effort, perhaps on the order of the Human Genome Project,” Hartung said.
As a first step to mapping the Human Toxome, Hartung and his collaborators have proposed tackling the pathways of endocrine disruption, a perturbation of the hormonal system that can cause tumors, birth defects and developmental disorders.
Since its inception, the NIH Director’s Award Program has funded a total of 406 High-Risk Research Awards: 111 Pioneer Awards since 2004, 216 New Innovator Awards since 2007 and 79 Transformative Research Projects Awards since 2009.
David March of Johns Hopkins Medicine and Tim Parsons of the Bloomberg School of Public Health contributed to this article.